待处理
入排:排除
图源:待检查
入排置信度 0.98
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.
Jean Francois Timsit, Mical Paul, Ryan K Shields, Roger Echols, Takamichi Baba, Yoshinori Yamano, Simon Portsmouth
Clin Infect Dis 75(6) 1081-1084
入排依据:未发现恶性肿瘤人群证据。
摘要
摘要
In the CREDIBLE-CR and APEKS-NP studies, cefiderocol treatment was effective against gram-negative bacteria producing metallo-B-lactamases; rates of clinical cure (70.8% [17/24]), microbiological eradication (58.3% [14/24]), and day 28 all-cause mortality (12.5% [3/24]) compared favorably with comparators of best-available therapy and high-dose meropenem (40.0% [4/10], 30.0% [3/10], and 50.0% [5/10], respectively).
KM 提取结果
0 个 Figure · 0 个 KM 面板